Please assess the completion status of the following clinical trial:

Trial Title: D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female~* Age 18-65 years~* Diagnosis of schizophrenia or schizoaffective disorder, depressed type~* Stable dose of antipsychotic for at least 4 weeks~* Able to provide informed consent~* Able to complete a cognitive battery~* Able to perform the cognitive remediation exercises~Exclusion Criteria:~* Current treatment with clozapine~* Dementia~* Seizure disorder~* Unstable medical illness~* Renal insufficiency measured as eGFR \>60mg/dL/min~* Active substance abuse: positive urine toxic screen~* Pregnancy, nursing, or unwilling to use appropriate birth control measures during participation if female and fertile.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- D-cycloserine (Type: EXPERIMENTAL): Participants will receive D-cycloserine weekly, one hour before the first cognitive remediation session of the week, for eight weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo weekly, one hour before the first cognitive remediation session of the week, for eight weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).